Assessment of comorbidity and structure of thyroid gland in patients with chronic metaplastic atrophic gastritis: review and own research

Authors

  • L.N. Mosiychuk State Institution “Institute of Gastroenterology of NAMS of Ukraine”, Dnipro, Ukraine
  • L.V. Demeshkina State Institution “Institute of Gastroenterology of NAMS of Ukraine”, Dnipro, Ukraine
  • I.S. Konenko State Institution “Institute of Gastroenterology of NAMS of Ukraine”, Dnipro, Ukraine
  • E.V. Zygalo State Institution “Institute of Gastroenterology of NAMS of Ukraine”, Dnipro, Ukraine
  • O.P. Petishko State Institution “Institute of Gastroenterology of NAMS of Ukraine”, Dnipro, Ukraine

DOI:

https://doi.org/10.22141/2308-2097.54.3.2020.211736

Keywords:

comorbidity, polymorbidity, autoimmune metaplastic atrophic gastritis, environmental metaplastic atrophic gastritis, thyroid gland, CIRS, ionizing radiation, iodine, risk factors, Hashimoto’s disease, autoimmune diseases, stomach cancer

Abstract

Background. Comorbidity remains a challenge for researchers. The frequency of comorbid diseases and the role of the thyroid gland (TG) in the etiopathogenesis in patients with metaplastic atrophic gastritis (MAG) are not finally determined. The purpose of the study was to assess comorbidity and thyroid structural changes in patients with MAG and to investigate the literature data on this problem. Materials and methods. The study enrolled 41 patients with MAG, among whom 29 women and 12 men. The patients’ age was (60.1 ± 2.4) years. They underwent gastroscopy with narrow-band imaging and gastric biopsy, an ultrasound examination of the thyroid gland. Comorbidity was studied using a questionnaire (Сumulative Illness Rating Scale, CIRS) and patients’ medical histories. Results. 82.9 % of patients with MAG had ultrasound diffuse thyroid chan­ges, which are firstly revealed in 48.8 % of them; 37.8% of observed patients had ultrasound thyroid diffuse changes combined with TG nodules. Besides, 9.8 % of patients had ultrasonic signs of Hashimoto’s disease (Hashimoto’s thyroiditis). 97.6 % of patients with MAG had polymorbidity, which was observed in 3 or more systems in 92.7 % of patients and in 2 systems in 4.9 %. Positive correlation (r = 0.412, p = 0.04) between patients’ age and CIRS score was established. According to CIRS data, the pathology of the upper and lower gastrointestinal tract was observed in 97.7 and 53.7 % of patients, respectively. Patients had comorbidity of the musculoskeletal and integumentary system (68.3 %), eyes, ears, throat, nose, and larynx (56.1 %), vascular system (56.1 %), heart diseases (51.2 %), and endocrine-metabolic patho­logy (34.1 %). Conclusions. 82.9 % of patients with MAG had ultrasound structural changes in the thyroid gland. Further research on autoimmune processes in the stomach and thyroid gland is needed to figure out a possible relationship between Hashimoto’s disease and autoimmune metaplastic atrophic gastritis, their pathogenesis, as well as the peculiarities of the course of these comorbid diseases. It is required to pay attention to MAG not only as of the disease, which can lead to stomach cancer development but also as a possible marker for comorbid thyroid pathology.

Downloads

Download data is not yet available.

References

Bakulin IG, Sayganov SA, Skalinskaya MI, Skazyvayeva EV, Lapinskii IV. Comorbid patient in gastroenterology: individual approach. Rational Pharmacotherapy in Cardiology. 2018;14(1):65-69. doi:10.20996/1819-6446-2018-14-1-65-69. (in Russian).

Fortin M, Ramond A, Boyd S, Almirall J. Disease, comorbidity and multimorbidity. In: Satariano WS, Maus M, editors. Aging, place, and health: a global perspective. Burlington, MA: Jones and Bartlett Learning; 2017. 164-193 pp.

World Health Organization (WHO). Multimorbidity: technical series on safer primary care. Geneva: WHO; 2016. 28 р.

Stirland LE, González-Saavedra L, Mullin DS, Ritchie CW, Muniz-Terrera G, Russ TC. Measuring multimorbidity beyond counting diseases: systematic review of community and population studies and guide to index choice. BMJ. 2020;368:m160. doi:10.1136/bmj.m160.

Makovski TT, Schmitz S, Zeegers MP, Stranges S, van den Akker M. Multimorbidity and quality of life: Systematic literature review and meta-analysis. Ageing Res Rev. 2019;53:100903. doi:10.1016/j.arr.2019.04.005.

Cassell A, Edwards D, Harshfield A, et al. The epidemiology of multimorbidity in primary care: a retrospective cohort study. Br J Gen Pract. 2018;68(669):e245-e251. doi:10.3399/bjgp18X695465.

Voronin SV, Cherkashin SV, Bersheva IV. Polymorbidity: definition, classifications, prevalence, estimation methods and practical significance. Vestnik rossiiskoi voenno-medicinskoi academii. 2018;(64):243-249. doi:10.17816/brmma12384. (in Russian).

Chukayeva II, Samorodskaya IV, Larina VN. The prevalence of multimorbidity: discussion about the terminology, registration and its effect on patient’s health care utilization. Terapevticheskii arkhiv. 2018;90(8):125-130. doi:10.26442/terarkh2018908125-130. (in Russian).

Almirall J, Fortin M. The coexistence of terms to describe the presence of multiple concurrent diseases. J Comorb. 2013;3:4-9. doi:10.15256/joc.2013.3.22.

Nurgazizova AK. The origin, development and current concepts of comorbidity and polymorbidity. Kazan medical journal. 2014;95(2):292-296. doi:10.17816/KMJ2084. (in Russian).

Willadsen TG, Bebe A, Køster-Rasmussen R, et al. The role of diseases, risk factors and symptoms in the definition of multimorbidity - a systematic review. Scand J Prim Health Care. 2016;34(2):112-121. doi:10.3109/02813432.2016.1153242.

Van der Akker M, Buntinx F, Knottnerus JA. Comorbidity or multimorbidity: what's in a name? A review of literature. Eur J Gen Pract. 1996;2(2):65-70. doi:10.3109/13814789609162146.

Lazebnik LB, Efremov LI, Konev YV. Semantic difficulties in polymorbidity. Clinical Gerontoloty. 2015;(3-4):44-46. (in Russian).

Vertkin АL. Komorbidnyi patsient: rukovodstvo dlia prakticheskikh vrachei [Comorbid patient: a guide for practitioners]. Moscow: Eksmo-press; 2015. 160 p. (in Russian).

Navickas R, Petric VK, Feigl AB, Seychell M. Multimorbidity: What do we know? What should we do? J Comorb. 2016;6(1):4-11. doi:10.15256/joc.2016.6.72.

Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi:10.1183/13993003.00547-2020.

Abrahamovych O, Fayura O, Abrahamovych U. Comorbidity: a modern view on the problem, classification (first notice). Lviv clinical bulletin. 2015;4(12):56-64. doi:10.25040/lkv2015.04.056. (in Ukrainian).

Fortin M, Bravo G, Hudon C, Vanasse A, Lapointe L. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med. 2005;3(3):223-228. doi:10.1370/afm.272.

Fortin M, Soubhi H, Hudon C, Bayliss EA, van den Akker M. Multimorbidity's many challenges. BMJ. 2007;334(7602):1016-1017. doi:10.1136/bmj.39201.463819.2C.

Voronin SV. Prevalence and features of polymorbidity of servicemen of different age groups according to the results of their medical examination to determine the category of fitness for military service. Vestnik rossiiskoi voenno-medicinskoi academii. 2020;(69):39-43. doi:10.17816/brmma25965. (in Russian).

Van Weel C, Schellevis FG. Comorbidity and guidelines: conflicting interests. Lancet. 2006;367(9510):550-551. doi:10.1016/S0140-6736(06)68198-1.

Sakib MN, Shooshtari S, St John P, Menec V. The prevalence of multimorbidity and associations with lifestyle factors among middle-aged Canadians: an analysis of Canadian Longitudinal Study on Aging data. BMC Public Health. 2019;19(1):243. doi:10.1186/s12889-019-6567-x.

Schäfer I, Hansen H, Kaduszkiewicz H, et al. Health behaviour, social support, socio-economic status and the 5-year progression of multimorbidity: results from the multicare cohort study. J. Comorbidity. 2019;(9):1-11. doi:10.1177/2235042X19883560.

Caughey GE, Roughead EE. Multimorbidity research challenges: where to go from here? J Comorb. 2011;1:8-10. doi:10.15256/joc.2011.1.9.

Gijsen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA. Causes and consequences of comorbidity: a review. J Clin Epidemiol. 2001;54(7):661-674. doi:10.1016/s0895-4356(00)00363-2.

Zhuravlev YI, Tkhorikova VN. T Current problems of measuring polymorbidity. Belgorod State University Scientific Bulletin. Medicine and Pharmacia. 2013;22(154):214-218. (in Russian).

Johnston MC, Crilly M, Black C, Prescott GJ, Mercer SW. Defining and measuring multimorbidity: a systematic review of systematic reviews. Eur J Public Health. 2019;29(1):182-189. doi:10.1093/eurpub/cky098.

Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16(5):622-626. doi:10.1111/j.1532-5415.1968.tb02103.x.

Uhlig K, Leff B, Kent D, et al. A framework for crafting clinical practice guidelines that are relevant to the care and management of people with multimorbidity. J Gen Intern Med. 2014;29(4):670-679. doi:10.1007/s11606-013-2659-y.

Lee SP, Sung IK, Kim JH, Lee SY, Park HS, Shim CS. The effect of emotional stress and depression on the prevalence of digestive diseases. J Neurogastroenterol Motil. 2015;21(2):273-282. doi:10.5056/jnm14116.

Al Quraan AM, Beriwal N, Sangay P, Namgyal T. The Psychotic Impact of Helicobacter pylori Gastritis and Functional Dyspepsia on Depression: A Systematic Review. Cureus. 2019;11(10):e5956. doi:10.7759/cureus.5956.

Locatelli F., Finocchio E, Marcon A, et al. The association between gastritis/gastroesophageal reflux and rhinitis/rhinosinusitis. European Respiratory Journal. 2016;48(Suppl 60): PA4255. doi:10.1183/13993003.congress-2016.PA4255.

Cellini M, Santaguida MG, Virili C, et al. Hashimoto's Thyroiditis and Autoimmune Gastritis. Front Endocrinol (Lausanne). 2017;8:92. doi:10.3389/fendo.2017.00092.

Neufeld M, Blizzard RM. Polyglandular autoimmune diseases. In: Pinchera A, Doniach D, Fenzi GF, Baschieri L, editors. Symposium on autoimmune aspects of endocrine disorders. New York: Academic Press; 1980. 357-365 pp.

Betterle C, Zanchetta R. Update on autoimmune polyendocrine syndromes (APS). Acta Biomed. 2003;74(1):9-33.

Betterle C, Garelli S, Coco G, Burra P. A rare combination of type 3 autoimmune polyendocrine syndrome (APS-3) or multiple autoimmune syndrome (MAS-3). Auto Immun Highlights. 2014;5(1):27-31. doi:10.1007/s13317-013-0055-6.

Rodriguez-Castro KI, Franceschi M, Miraglia C, et al. Autoimmune diseases in autoimmune atrophic gastritis. Acta Biomed. 2018;89(8-S):100-103. doi:10.23750/abm.v89i8-S.7919.

Park JY, Lam-Himlin D, Vemulapalli R. Review of autoimmune metaplastic atrophic gastritis. Gastrointest Endosc. 2013;77(2):284-292. doi:10.1016/j.gie.2012.09.033.

Minalyan A, Benhammou JN, Artashesyan A, Lewis MS, Pisegna JR. Autoimmune atrophic gastritis: current perspectives. Clin Exp Gastroenterol. 2017;10:19-27. doi:10.2147/CEG.S109123.

Pittman ME, Voltaggio L, Bhaijee F, Robertson SA, Montgomery EA. Autoimmune Metaplastic Atrophic Gastritis: Recognizing Precursor Lesions for Appropriate Patient Evaluation. Am J Surg Pathol. 2015;39(12):1611-1620. doi:10.1097/PAS.0000000000000481.

Zorzetto V, Maddalo G, Basso D, Farinati F. Immunotherapy for gastric premalignant lesions and cancer. Immunotherapy. 2012;4(6):587-599. doi:10.2217/imt.12.50.

Crafa P, Russo M, Miraglia C, et al. From Sidney to OLGA: an overview of atrophic gastritis. Acta Biomed. 2018;89(8-S):93-99. doi:10.23750/abm.v89i8-S.7946.

Jencks DS, Adam JD, Borum ML, Koh JM, Stephen S, Doman DB. Overview of Current Concepts in Gastric Intestinal Metaplasia and Gastric Cancer. Gastroenterol Hepatol (N Y). 2018;14(2):92-101.

Calcaterra V, Montalbano C, Miceli E, et al. Anti-gastric parietal cell antibodies for autoimmune gastritis screening in juvenile autoimmune thyroid disease. J Endocrinol Invest. 2020;43(1):81-86. doi:10.1007/s40618-019-01081-y.

Utiyama SRR, De Bem RS, Skare TL, et al. Anti-parietal cell antibodies in patients with autoimmune thyroid diseases. J Endocrinol Invest. 2018;41(5):523-529. doi:10.1007/s40618-017-0755-2.

Miceli E, Vanoli A, Lenti MV, et al. Natural history of autoimmune atrophic gastritis: a prospective, single centre, long-term experience. Aliment Pharmacol Ther. 2019;50(11-12):1172-1180. doi:10.1111/apt.15540.

Astl J, Šterzl I. Activation of Helicobacter pylori causes either autoimmune thyroid diseases or carcinogenesis in the digestive tract. Physiol Res. 2015;64(Suppl 2):S291-S301. doi:10.33549/physiolres.933118.

Erdoğan A, Yilmaz U. Is there a relationship between Helicobacter pylori and gastric autoimmunity? Turk J Gastroenterol. 2011;22(2):134-138. doi:10.4318/tjg.2011.0181.

Gao Y, Liu S. Research the relativity of Helicobacter pylori infection and autoimmune thyroiditis. Journal of Dalian Medical University. 2013;(2):160-162. doi:10.11724/jdmu.2013.02.16. (in Chinese).

Arslan MS, Ekiz F, Deveci M, et al. The relationship between cytotoxin-associated gene A positive Helicobacter pylori infection and autoimmune thyroid disease. Endocr Res. 2015;40(4):211-214. doi:10.3109/07435800.2015.1015727.

Shi WJ, Liu W, Zhou XY, Ye F, Zhang GX. Associations of Helicobacter pylori infection and cytotoxin-associated gene A status with autoimmune thyroid diseases: a meta-analysis. Thyroid. 2013;23(10):1294-1300. doi:10.1089/thy.2012.0630.

Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-1367. doi:10.1136/gutjnl-2015-309252.

Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365-388. doi:10.1055/a-0859-1883.

Testerman TL, Morris J. Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol. 2014;20(36):12781-12808. doi:10.3748/wjg.v20.i36.12781.

Smyk DS, Koutsoumpas AL, Mytilinaiou MG, Rigopoulou EI, Sakkas LI, Bogdanos DP. Helicobacter pylori and autoimmune disease: cause or bystander. World J Gastroenterol. 2014;20(3):613-629. doi:10.3748/wjg.v20.i3.613.

Hou Y, Sun W, Zhang C, et al. Meta-analysis of the correlation between Helicobacter pylori infection and autoimmune thyroid diseases. Oncotarget. 2017;8(70):115691-115700. doi:10.18632/oncotarget.22929.

Bassi V, Santinelli C, Iengo A, Romano C. Identification of a correlation between Helicobacter pylori infection and Graves' disease. Helicobacter. 2010;15(6):558-562. doi:10.1111/j.1523-5378.2010.00802.x.

Bertalot G, Montresor G, Tampieri M, et al. Decrease in thyroid autoantibodies after eradication of Helicobacter pylori infection. Clin Endocrinol (Oxf). 2004;61(5):650-652. doi:10.1111/j.1365-2265.2004.02137.x.

Gravina AG, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M. Helicobacter pylori and extragastric diseases: A review. World J Gastroenterol. 2018;24(29):3204-3221. doi:10.3748/wjg.v24.i29.3204.

Papamichael KX, Papaioannou G, Karga H, Roussos A, Mantzaris GJ. Helicobacter pylori infection and endocrine disorders: is there a link? World J Gastroenterol. 2009;15(22):2701-2707. doi:10.3748/wjg.15.2701.

Bobyrova LE, Gorodinskaya OY. Thyroid pathology and iodine supply condition in the Poltava region in 20 years after Chernobyl disaster. World of Medicine and Biology. 2014;(43):8-14. (in Ukrainian).

Behrouzian R, Aghdami N. Urinary iodine/creatinine ratio in patients with stomach cancer in Urmia, Islamic Republic of Iran. East Mediterr Health J. 2004;10(6):921-924.

Gulaboglu M, Yildiz L, Gul M, Celebi F, Peker K. Blood and urine iodine levels in patients with gastric cancer. Biol Trace Elem Res. 2006;113(3):261-271. doi:10.1385/BTER:113:3:261.

Tabaeizadeh M, Haghpanah V, Keshtkar A, et al. Goiter frequency is more strongly associated with gastric adenocarcinoma than urine iodine level. J Gastric Cancer. 2013;13(2):106-110. doi:10.5230/jgc.2013.13.2.106.

Kovacheva-Slavova MD, Angelov TA, Valkov HYa, Iliev HI, Vladimirov BV. Current view on autoimmune gastritis. In: Roesler BM, editor. Gastritis: new approach and treatments. London: IntechOpen; 2019. doi:10.5772/intechopen.87006. 374 p.

Annibale B, Esposito G, Lahner E. A current clinical overview of atrophic gastritis. Expert Rev Gastroenterol Hepatol. 2020;14(2):93-102. doi:10.1080/17474124.2020.1718491.

Feldman M, Lee EL. Gastritis. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management. 10th ed. Philadelphia, PA: Elsevier Saunders; 2016. 868-883 pp.

Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis--pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013;10(9):529-541. doi:10.1038/nrgastro.2013.101.

Kandemir EG, Yonem A, Narin Y. Gastric carcinoma and thyroid status. J Int Med Res. 2005;33(2):222-227. doi:10.1177/147323000503300210.

Venturi S, Venturi A, Cimini D, Arduini C, Venturi M, Guidi A. A new hypothesis: iodine and gastric cancer. Eur J Cancer Prev. 1993;2(1):17-23.

Venturi S, Donati FM, Venturi A, Venturi M, Grossi L, Guidi A. Role of iodine in evolution and carcinogenesis of thyroid, breast and stomach. Adv Clin Path. 2000;4(1):11-17.

Gulaboglu M, Yildiz L, Celebi F, Gul M, Peker K. Comparison of iodine contents in gastric cancer and surrounding normal tissues. Clin Chem Lab Med. 2005;43(6):581-584. doi:10.1515/CCLM.2005.101.

Iashina IN, Ivanov AV, Kharchenko VV, Litvinova ES. Embriogenez organov pishchevaritel'noi sistemy cheloveka: anomalii razvitiia [Embryogenesis of the human digestive system: developmental anomalies]. Kursk; 2012. 77 p. (in Russian).

Dzhikiya EL, Avilov ON, Kiseleva YaYu, Kulinich TM, Bozhenko VK. Sodium/iodide symporter (NIS): structure, function and role in in thyroid diseases. Vestnik Rossijskogo naučnogo centra rentgenoradiologii. 2018;18(1):3. (in Russian).

Altorjay A, Dohán O, Szilágyi A, Paroder M, Wapnir IL, Carrasco N. Expression of the Na+/I- symporter (NIS) is markedly decreased or absent in gastric cancer and intestinal metaplastic mucosa of Barrett esophagus. BMC Cancer. 2007;7:5. doi:10.1186/1471-2407-7-5.

Ruf J, Carayon P. Structural and functional aspects of thyroid peroxidase. Arch Biochem Biophys. 2006;445(2):269-277. doi:10.1016/j.abb.2005.06.023.

Bhattacharjee M, Bhattacharjee S, Gupta A, Banerjee RK. Critical role of an endogenous gastric peroxidase in controlling oxidative damage in H. pylori-mediated and nonmediated gastric ulcer. Free Radic Biol Med. 2002;32(8):731-743. doi:10.1016/s0891-5849(02)00757-8.

Tessler FN, Middleton WD, Grant EG. Thyroid Imaging Reporting and Data System (TI-RADS): A User's Guide. Radiology. 2018;287(1):29-36.

Mamaev AN. Osnovy meditsinskoi statistiki [Fundamentals of medical statistics]. Moscow: Prakticheskaia Meditsina; 2011. 128 p. (in Russian).

Martirosian IT. Kliniko-morfologicheskaia kharakteristika ochagovykh (fokal'nykh) izmenenii tkani shchitovidnoi zhelezy v usloviiakh legkogo iodnogo defitsita. Diss. kand. med. Nauk [Clinical and morphological characteristics of focal (focal) changes in thyroid tissue in conditions of mild iodine deficiency. PhD in med sci diss.]. Moscow; 2007. 25 p. (in Russian).

Korzun VN, Parac AM. Ways of minimization of the effect of radiation and endemic factors on the population’s health state. Environment and health. 2006;(1):13-17. (in Ukrainian).

Kozjarin IP, Korzun VN. Medical and social problems of prophylaxis of iodine deficiency. Mystectvo likuvannja. 2009;(60):39-43. (in Ukrainian).

Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders. Lancet Diabetes Endocrinol. 2015;3(4):286-295. doi:10.1016/S2213-8587(14)70225-6.

Leung AM, Braverman LE. Iodine-induced thyroid dysfunction. Curr Opin Endocrinol Diabetes Obes. 2012;19(5):414-419. doi:10.1097/MED.0b013e3283565bb2.

Murphy R, Turek C, Arseneau L. The role of iodine deficiency and subsequent repletion in autoimmune thyroid disease and thyroid cancer. JRM. 2016;5(1):32-38. doi:10.14200/jrm.2016.5.0102.

Sun X, Shan Z, Teng W. Effects of increased iodine intake on thyroid disorders. Endocrinol Metab (Seoul). 2014;29(3):240-247. doi:10.3803/EnM.2014.29.3.240.

Kravchenko VI. Chornobyl accident and iodine deficiency as risk factor of thyroid pathology in population of the affected regions of Ukraine. Mìžnarodnij endokrinologìčnij žurnal. 2016; (76):13-20. doi:10.22141/2224-0721.2.74.2016.70911. (in Ukrainian).

Vasko LM, Pocherniayeva VF, Bashtan VP. Zasoby zahystu organizmu vid dii' ionizuval'nogo vyprominjuvannja: navchal'nyj posibnyk [Means of protecting the body from the effects of ionising radiation: a tutorial]. Kyiv: Medycyna; 2019. 112 p. (in Ukrainian).

World Nuclear Association. World Uranium Mining Production. Available from: https://www.world-nuclear.org/information-library/nuclear-fuel-cycle/mining-of-uranium/world-uranium-mining-production.aspx. Accessed: August 2019.

Tkachenko VI, Maksymets YaA, Vydyborets NV, Kovalenko OF. Analysis of the prevalence and morbidity of thyroid pathology among the population of Kyiv region and Ukraine for 2007-2017. Mìžnarodnij endokrinologìčnij žurnal. 2018;14(3):272-277. doi:10.22141/2224-0721.14.3.2018.136426. (in Ukrainian).

Prilutskii AS, Kasiarum VP, Bakhtiiarova AA, Kushch OM, Mailian EA, Buzhina LM. Frequency of thyroid diseases in the Donetsk region. Mìžnarodnij endokrinologìčnij žurnal. 2009;(21):2-15. (in Russian).

Maser C, Toset A, Roman S. Gastrointestinal manifestations of endocrine disease. World J Gastroenterol. 2006;12(20):3174-3179. doi:10.3748/wjg.v12.i20.3174.

Paz-Filho G, Mastronardi CA. Interactions between the endocrine system and the gastrointestinal tract. Transl Gastrointest Cancer. 2015;4(1):1-2. doi:10.3978/ j.issn.2224-4778.2014.09.04.

Carballo GA, Fighera TM. Effect of gastrointestinal disorders in autoimmune thyroid diseases. Transl Gastrointest Cancer. 2015;4(1):76-82. doi:10.3978/j.issn.2224-4778.2014.07.03.

Chen S, Ying L, Kong M, Zhang Y, Li Y. The Prevalence of Helicobacter pylori Infection Decreases with Older Age in Atrophic Gastritis. Gastroenterol Res Pract. 2013;2013:494783. doi:10.1155/2013/494783.

Yancik R, Ershler W, Satariano W, Hazzard W, Cohen HJ, Ferrucci L. Report of the national institute on aging task force on comorbidity. J Gerontol A Biol Sci Med Sci. 2007;62(3):275-280. doi:10.1093/gerona/62.3.275.

Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430-439. doi:10.1016/j.arr.2011.03.003.

Published

2021-09-06

How to Cite

Mosiychuk, L., Demeshkina, L., Konenko, I., Zygalo, E., & Petishko, O. (2021). Assessment of comorbidity and structure of thyroid gland in patients with chronic metaplastic atrophic gastritis: review and own research. GASTROENTEROLOGY, 54(3), 155–171. https://doi.org/10.22141/2308-2097.54.3.2020.211736

Issue

Section

Original Researches

Most read articles by the same author(s)

1 2 3 4 5 > >>